<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Barrett's <z:mpath ids='MPATH_160'>metaplasia</z:mpath> consists of columnar epithelium that replaces the <z:mpath ids='MPATH_458'>normal</z:mpath> esophageal mucosa in patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0002020'>gastroesophageal reflux</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Because intestinal-type Barrett's <z:mpath ids='MPATH_160'>metaplasia</z:mpath> is the major risk factor for <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> development, understanding the mechanisms that predispose the esophageal mucosa to malignant degeneration is clinically important </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="16856">Glutathione</z:chebi> s-transferase (GST)-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">pi</z:e> belongs to a class of protective enzymes whose activity has been shown to be much lower in Barrett's <z:mpath ids='MPATH_160'>metaplasia</z:mpath> than in the <z:mpath ids='MPATH_458'>normal</z:mpath> esophagus, where this form of GST is predominant </plain></SENT>
<SENT sid="3" pm="."><plain>In the studies described here, using immunocytochemical analysis, we observed higher levels of cytoplasmic GST-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">pi</z:e> protein in <z:mpath ids='MPATH_458'>normal</z:mpath> esophageal mucosa than in Barrett's <z:mpath ids='MPATH_160'>metaplasia</z:mpath> </plain></SENT>
<SENT sid="4" pm="."><plain>Using northern blot analysis, we also observed lower GST-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">pi</z:e> <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels in Barrett's <z:mpath ids='MPATH_160'>metaplasia</z:mpath> than in <z:mpath ids='MPATH_458'>normal</z:mpath> esophagus or <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> from the same patients </plain></SENT>
<SENT sid="5" pm="."><plain>Using as model systems three Barrett's <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> cell lines and short-term organ culture of freshly resected <z:mpath ids='MPATH_458'>normal</z:mpath> esophagus and Barrett's <z:mpath ids='MPATH_160'>metaplasia</z:mpath>, dose-dependent induction of GST-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">pi</z:e> <z:chebi fb="2" ids="33699">mRNA</z:chebi> was observed by using butylated hydroxyanisole and <z:chebi fb="0" ids="41879">dexamethasone</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>GST-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">pi</z:e> <z:chebi fb="2" ids="33699">mRNA</z:chebi> in Barrett's <z:mpath ids='MPATH_160'>metaplasia</z:mpath> was induced up to 2.5-fold with 60 microM butylated hydroxyanisole and nearly fivefold with 320 nM <z:chebi fb="0" ids="41879">dexamethasone</z:chebi> after 24 h </plain></SENT>
<SENT sid="7" pm="."><plain>These studies demonstrate the ability to induce protective GST-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">pi</z:e> in Barrett's <z:mpath ids='MPATH_160'>metaplasia</z:mpath> and may suggest a mechanism for future chemoprevention studies in patients with this type of epithelium, which is at high risk for malignant degeneration </plain></SENT>
</text></document>